Switch to injectable cabotegravir-rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial
Listen to this summary
The study aimed to evaluate the efficacy and safety of long-acting injectable (LAI) cabotegravir-rilpivirine compared to daily oral antiretroviral therapy (TLD) in adolescents living with HIV who have achieved virological suppression. Results showed that LAI cabotegravir-rilpivirine was not only non-inferior but also superior to TLD in maintaining virological suppression over 96 weeks, with no new safety concerns identified. These findings suggest that LAI cabotegravir-rilpivirine could be a viable maintenance treatment option for this population in sub-Saharan Africa.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from Lancet (London, England)
View all →Sep 22, 2026 · Lancet (London, England)
Current advancements in the care of peripheral arterial disease: modern approaches to medical, endovascular, and surgical treatment
Sep 22, 2026 · Lancet (London, England)
Understanding peripheral arterial disease in the current era
Sep 22, 2026 · Lancet (London, England)
Peripheral arterial disease: adverse impacts, disparities in outcomes, and the path ahead
Sep 21, 2026 · Lancet (London, England)
Developing roadmaps for advancing practice, research, and policy in the arts and health
Sep 18, 2026 · Lancet (London, England)
Precision prevention and early detection: framework for a new clinical cancer control pathway
Sep 13, 2026 · Lancet (London, England)
Most-favoured-nation pricing for prescription drugs in US Medicare: a cohort study
More in Nuclear Medicine
View all →Sep 23, 2026 · The New England journal of medicine
Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis
Sep 23, 2026 · The New England journal of medicine
Etuvetidigene Autotemcel for the Treatment of Wiskott-Aldrich Syndrome
Sep 23, 2026 · The New England journal of medicine
Clinical Uses of Common Genetic Variants Associated with Common Diseases
Sep 23, 2026 · The New England journal of medicine
Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma
Sep 18, 2026 · Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
CMR and FDG PET/CT Imaging Phenotypes and their Association with Outcomes in Patients with Known or Suspected Myocarditis
Sep 14, 2026 · The New England journal of medicine
Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
